Site notifications

Sub menu

 
 

IMFINZI (AstraZeneca Pty Ltd)

Product name
IMFINZI
Sponsor
AstraZeneca Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
221 working days (225)
Active ingredients
durvalumab
Registration type
EOI
Indication
Small cell lung cancer (SCLC)

IMFINZI (solution for injection) in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Help us improve this page